Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Balance Sheet: Assets 
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Abiomed Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Cash and cash equivalents 182,335 180,492 132,818 144,255 241,882 175,454 232,710 181,018 202,241 214,827 192,341 117,970 150,279 101,048 121,021 84,181 76,382 61,288 42,975 50,502 44,536 43,970 39,040 61,069 54,709 38,274
Short-term marketable securities 638,037 663,829 625,789 524,966 408,677 347,577 350,985 305,434 330,843 212,536 250,775 309,569 295,041 385,624 370,677 373,975 334,064 299,228 319,274 250,751 218,661 207,441 190,908 179,640 178,236 184,900
Accounts receivable, net 94,475 91,102 90,608 88,952 89,568 88,645 97,179 92,990 80,909 82,084 84,650 100,994 94,319 86,206 90,809 88,215 74,201 67,511 70,010 64,862 57,327 53,557 54,055 50,178 46,607 41,280
Inventories, net 102,237 95,373 93,981 90,199 85,986 83,661 81,059 82,448 83,209 89,284 90,088 91,193 90,295 87,726 80,942 71,808 63,656 55,781 50,204 46,891 40,632 36,926 34,931 32,053 31,491 29,093
Prepaid expenses and other current assets 45,714 29,563 33,277 36,634 45,374 34,536 26,032 31,801 19,419 20,958 18,009 16,850 17,498 16,761 13,748 10,549 13,296 13,489 11,808 9,192 9,014 9,021 8,024 10,479 8,827 6,741
Current assets 1,062,798 1,060,359 976,473 885,006 871,487 729,873 787,965 693,691 716,621 619,689 635,863 636,576 647,432 677,365 677,197 628,728 561,599 497,297 494,271 422,198 370,170 350,915 326,958 333,419 319,870 300,288
Long-term marketable securities 116,871 159,876 220,089 262,635 210,979 281,776 264,085 301,315 202,613 169,668 207,795 167,981 106,025 40,032 21,718 6,887 37,502 49,485 55,954 37,669 47,143 18,240 4,004
Property and equipment, net 195,157 198,478 202,490 196,880 197,184 198,234 197,129 179,364 175,582 170,346 164,931 162,060 157,896 151,654 145,005 138,455 134,065 127,324 117,167 107,977 97,697 92,804 87,777 60,909 50,207 25,950
Goodwill 72,960 74,855 76,786 77,449 78,166 79,006 78,568 79,691 78,122 76,783 31,969 32,594 31,727 33,035 32,601 33,260 33,719 33,948 35,808 34,814 34,332 33,199 31,045 30,562 32,582 32,272
Other intangibles, net 36,833 38,168 39,518 40,278 41,062 41,904 42,150 43,327 42,895 42,223 14,913 15,205 14,800 15,411 15,208 15,516 15,730 15,837 16,705 16,241 16,016 15,487 14,482 14,257 15,199 15,055
Deferred tax assets 18,881 17,096 10,552 3,680 2,975 4,958 11,380 21,233 29,547 30,875 43,336 47,028 67,277 66,743 77,502 96,450 116,248 115,049 70,746 75,201 106,798 113,457 34,723 39,007 48,614 51,296
Other assets 193,044 154,804 147,485 126,949 128,181 122,643 113,082 109,813 82,594 139,928 117,655 135,167 99,191 140,820 85,115 44,707 25,804 15,697 14,176 13,686 13,686 8,686 8,286 4,570 4,422 4,451
Long-term assets 633,746 643,277 696,920 707,871 658,547 728,521 706,394 734,743 611,353 629,823 580,599 560,035 476,916 447,695 377,149 328,388 325,566 314,742 292,104 297,404 324,483 301,302 223,456 167,545 155,028 129,024
Total assets 1,696,544 1,703,636 1,673,393 1,592,877 1,530,034 1,458,394 1,494,359 1,428,434 1,327,974 1,249,512 1,216,462 1,196,611 1,124,348 1,125,060 1,054,346 957,116 887,165 812,039 786,375 719,602 694,653 652,217 550,414 500,964 474,898 429,312

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Abiomed Inc. current assets increased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.
Property and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Abiomed Inc. property and equipment, net decreased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Abiomed Inc. long-term assets decreased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Abiomed Inc. total assets increased from Q4 2022 to Q1 2023 but then slightly decreased from Q1 2023 to Q2 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Abiomed Inc. cash and cash equivalents increased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.
Short-term marketable securities Amount of investment in marketable security, classified as current. Abiomed Inc. short-term marketable securities increased from Q4 2022 to Q1 2023 but then slightly decreased from Q1 2023 to Q2 2023 not reaching Q4 2022 level.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Abiomed Inc. accounts receivable, net increased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.
Inventories, net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Abiomed Inc. inventories, net increased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.